2025
Lipid Peroxidation and Glutathione Levels Among People Living With HIV Co‐infected With Human Coronaviruses in Ghana
Amegashie E, Kwayisi‐Darkwah C, Adusei‐Poku M, Sikeola R, Ativi L, Ahene A, Atampugbire G, Tagoe E, Paintsil E, Torpey K, Quaye O. Lipid Peroxidation and Glutathione Levels Among People Living With HIV Co‐infected With Human Coronaviruses in Ghana. Journal Of Medical Virology 2025, 97: e70301. PMID: 40110873, DOI: 10.1002/jmv.70301.Peer-Reviewed Original ResearchMeSH KeywordsAdultCoinfectionCoronavirus InfectionsCross-Sectional StudiesCyclopropanesDideoxyadenosineDideoxynucleosidesFemaleGhanaGlutathioneHeterocyclic Compounds, 3-RingHIV InfectionsHumansLipid PeroxidationMaleMalondialdehydeMiddle AgedOxazinesOxidative StressPiperazinesProspective StudiesPyridonesYoung AdultConceptsHuman immunodeficiency virusHuman immunodeficiency virus co-infectionCo-infectionGSH levelsART-experienced individualsPLWH co-infectedHuman coronavirusesHIV co-infectionHIV-negative individualsMalondialdehyde levelsOxidative stressOxidative stress markersIncreased MDA levelsCross-sectional studyOro-pharyngeal swabsImmunodeficiency virusGhanaian patientsMono-infectionReduced GSH levelsTreatment strategiesPlasma samplesDisease severityMDA levelsStress markersTailored monitoring
2024
Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses
Yang Y, Li F, Du L. Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses. Journal Of Nanobiotechnology 2024, 22: 304. PMID: 38822339, PMCID: PMC11140877, DOI: 10.1186/s12951-024-02573-7.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, NeutralizingAntibodies, ViralBetacoronavirusCoronavirus InfectionsCOVID-19HumansMiddle East Respiratory Syndrome CoronavirusPandemicsPneumonia, ViralSARS-CoV-2Severe acute respiratory syndrome-related coronavirusSingle-Domain AntibodiesSpike Glycoprotein, CoronavirusVirus InternalizationConceptsReceptor-binding domainPathogenic human CoVsHeavy-chain antibodiesSARS-CoV-2Development of nanobiotechnologiesPathogenic human coronavirusesSingle-domain antibodiesSARS-CoV-2 variantsS proteinViral entry processHuman CoVsViral spikeReemerging pathogensEvaluation of therapeutic agentsSARS-CoVVirus pathogenesisVariable domainsNanobodiesViral structuresPandemic potentialMERS-CoVPathogenic coronavirusesViral entryBinding affinityHuman coronaviruses
2023
DYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner
Strine M, Cai W, Wei J, Alfajaro M, Filler R, Biering S, Sarnik S, Chow R, Patil A, Cervantes K, Collings C, DeWeirdt P, Hanna R, Schofield K, Hulme C, Konermann S, Doench J, Hsu P, Kadoch C, Yan Q, Wilen C. DYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner. PLOS Biology 2023, 21: e3002097. PMID: 37310920, PMCID: PMC10263356, DOI: 10.1371/journal.pbio.3002097.Peer-Reviewed Original ResearchConceptsGenome-wide CRISPR/Cas9 screenCRISPR/Cas9 screenPathogenic human coronavirusesKinase-independent mannerRegulated kinase 1AProviral host factorNovel drug targetsMultiple cell typesDNA accessibilityHost factorsKinase functionHuman coronavirusesHost genesDistal enhancerNovel regulatorCas9 screenKinase 1AGene expressionNeuronal developmentDYRK1ADrug targetsDiverse coronavirusesProviral activityCell typesSevere acute respiratory syndrome coronavirus 2
2021
The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study
Townsend JP, Hassler HB, Wang Z, Miura S, Singh J, Kumar S, Ruddle NH, Galvani AP, Dornburg A. The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study. The Lancet Microbe 2021, 2: e666-e675. PMID: 34632431, PMCID: PMC8486316, DOI: 10.1016/s2666-5247(21)00219-6.Peer-Reviewed Original ResearchConceptsDurability of immunitySARS-CoV-2Human-infecting coronavirusesProbability of reinfectionAntibody levelsMERS-CoVSARS-CoVLong-term immune responsePeak antibody responsePublic health decision makingCOVID-19 pandemic continuesEndemic conditionsCOVID-19 morbidityPublic health measuresVirus SARS-CoVHealth decision makingOptical density levelsDevastating COVID-19 pandemicAntibody declineLikely reinfectionAntibody responseEndemic coronavirusesHCoV-NL63Immune responseHuman coronavirusesImmunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines
Wisnewski AV, Redlich CA, Liu J, Kamath K, Abad QA, Smith RF, Fazen L, Santiago R, Luna J, Martinez B, Baum-Jones E, Waitz R, Haynes WA, Shon JC. Immunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines. PLOS ONE 2021, 16: e0252849. PMID: 34499652, PMCID: PMC8428655, DOI: 10.1371/journal.pone.0252849.Peer-Reviewed Original ResearchConceptsCOVID-19 mRNA vaccine recipientsLinear epitopesSARS-CoV-2 neutralizationCOVID-19 mRNA vaccinesVaccine-induced IgGMRNA vaccine recipientsSARS-CoV-2 spike proteinDominant linear epitopeElicit IgGVaccine recipientsVaccine effectivenessMRNA vaccinesVaccination samplesImmune escapeHuman coronavirusesHealthy adultsSARS-CoVVaccine epitopesCritical epitopesAdverse responsesReverse vaccinologySpike proteinNatural infectionS2 subunitIgGTranslational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein
Hsu JC, Laurent-Rolle M, Pawlak JB, Wilen CB, Cresswell P. Translational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2101161118. PMID: 34045361, PMCID: PMC8214666, DOI: 10.1073/pnas.2101161118.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Interferon-stimulated genesImmune responseSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Host protein synthesisRespiratory syndrome coronavirus 2Syndrome coronavirus 2Innate immune responseUnprecedented global health crisisCoronavirus 2N7-methyltransferase activityOngoing COVID-19 pandemicHuman coronavirusesTranslational shutdownVirus replicationNsp14 proteinGlobal health crisisProtein synthesisInhibition activityCausative agentCOVID-19COVID-19 pandemicSARS-CoV-2 nsp14Dependent induction
2020
Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2
Xiao X, Wang C, Chang D, Wang Y, Dong X, Jiao T, Zhao Z, Ren L, Dela Cruz CS, Sharma L, Lei X, Wang J. Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2. Frontiers In Immunology 2020, 11: 586572. PMID: 33324406, PMCID: PMC7723961, DOI: 10.3389/fimmu.2020.586572.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Therapeutic agentsAnti-coronaviral activitySARS-CoV-2 drugsWide therapeutic windowCOVID-19 infectionNovel therapeutic agentsEffective compoundsTherapeutic optionsReplication of coronavirusesSafe drugSevere diseaseTherapeutic windowHuman coronavirusesTherapeutic candidateUS FDAArbidol hydrochlorideIdentification of PotentTwo-step screenMillions of peopleSafety indexDrugsCOVID-19 pandemicFDACoronavirusA dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
Rambaut A, Holmes E, O’Toole Á, Hill V, McCrone J, Ruis C, du Plessis L, Pybus O. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nature Microbiology 2020, 5: 1403-1407. PMID: 32669681, PMCID: PMC7610519, DOI: 10.1038/s41564-020-0770-5.Peer-Reviewed Original ResearchConceptsDiversity of SARS-CoV-2Virus lineagesVirus genome sequencesSARS-CoV-2 lineagesPhylogenetic frameworkGenome sequencePhylogenetic diversityGlobal spread of SARS-CoV-2Nomenclatural proposalsGenomic epidemiologyVirus nomenclatureSARS-CoV-2LineagesLineage labelingHuman coronavirusesGlobal spreadNomenclatureSequenceSpread of SARS-CoV-2VirusType I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19
Park A, Iwasaki A. Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19. Cell Host & Microbe 2020, 27: 870-878. PMID: 32464097, PMCID: PMC7255347, DOI: 10.1016/j.chom.2020.05.008.Peer-Reviewed Original ResearchConceptsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Syndrome coronavirus 2Role of interferonType ICoronavirus disease 2019COVID-19Innate antiviral responseOngoing global threatCoronavirus 2Pathogenic coronavirusesTreatment strategiesDisease 2019Protective effectHuman coronavirusesRecombinant interferonMERS-CoVSARS-CoVAntiviral responseInterferonAntiviral therapeuticsCombat COVID-19Interferon inductionGlobal pandemic
2017
Transmission Dynamics of Respiratory Viruses in a Congregated Military Population: Prospective Cohort Study
Lewnard J, Chen W, Milzman J, Grigorenko E, Robinson S, Jones C, Moreno N, Malone L, Weinberger D, Burgess T, Coles C. Transmission Dynamics of Respiratory Viruses in a Congregated Military Population: Prospective Cohort Study. Open Forum Infectious Diseases 2017, 4: s238-s238. PMCID: PMC7107105, DOI: 10.1093/ofid/ofx163.503.Peer-Reviewed Original ResearchNon-polio enterovirusesRespiratory virusesHCoV-229EHCoV-OC43Military recruitsAcute respiratory infectionsProspective cohort studyCommon respiratory virusesSource of transmissionCohort studyRespiratory infectionsViral sheddingAsymptomatic sheddingImmune protectionImmune responseHuman coronavirusesNasal samplesEconomic burdenRhinovirusMilitary populationSecond monthBasic trainingFirst weekPrevious exposureWidespread transmission
2006
Coronavirus HKU1 Infection in the United States - Volume 12, Number 5—May 2006 - Emerging Infectious Diseases journal - CDC
Esper F, Weibel C, Ferguson D, Landry ML, Kahn JS. Coronavirus HKU1 Infection in the United States - Volume 12, Number 5—May 2006 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2006, 12: 775-779. PMID: 16704837, PMCID: PMC3374449, DOI: 10.3201/eid1205.051316.Peer-Reviewed Original ResearchConceptsHCoV-HKU1Respiratory specimensLower respiratory tract infectionsLower respiratory tract diseaseHCoV-HKU1 infectionRespiratory tract infectionsRespiratory syncytial virusRespiratory tract diseaseReverse transcription-polymerase chain reactionNew human coronavirusYears of ageTranscription-polymerase chain reactionTract infectionsSyncytial virusPositive childrenParainfluenza virusTract diseaseRespiratory tractHuman coronavirusesPositive specimensInfluenza virusInfectionChain reactionChildrenVirus
2005
Association between a Novel Human Coronavirus and Kawasaki Disease
Esper F, Shapiro ED, Weibel C, Ferguson D, Landry ML, Kahn JS. Association between a Novel Human Coronavirus and Kawasaki Disease. The Journal Of Infectious Diseases 2005, 191: 499-502. PMID: 15655771, PMCID: PMC7199489, DOI: 10.1086/428291.Peer-Reviewed Original ResearchConceptsKawasaki diseaseNovel human coronavirusRespiratory secretionsHuman coronavirusesClassic Kawasaki diseaseNew Haven coronavirusCase-control studyReverse transcriptase-polymerase chain reactionSystemic vasculitisControl subjectsPolymerase chain reactionPossible associationDiseaseChain reactionInfectionCoronavirusSecretionAssociationVasculitisInfantsEtiologyEvidence of a Novel Human Coronavirus That Is Associated with Respiratory Tract Disease in Infants and Young Children
Esper F, Weibel C, Ferguson D, Landry ML, Kahn JS. Evidence of a Novel Human Coronavirus That Is Associated with Respiratory Tract Disease in Infants and Young Children. The Journal Of Infectious Diseases 2005, 191: 492-498. PMID: 15655770, PMCID: PMC7199485, DOI: 10.1086/428138.Peer-Reviewed Original ResearchConceptsRespiratory tract diseaseTract diseaseNovel human coronavirusHuman coronavirusesYoung childrenNew Haven coronavirusAbnormal breath soundsClinical featuresSymptomatic childrenPolymerase chain reactionRespiratory specimensRespiratory tractCommon findingBreath soundsAnimal CoVsHCoVsNew HavenDiseaseInfantsEtiological agentSubstantial proportionChain reactionChildrenSignificant proportionInfection
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply